Sign in

Trial result ·

Dupilumab Improves Endoscopic Features in Adult and Adolescent Patients with Eosinophilic Esophagitis: Post Hoc Analysis of LIBERTY EoE TREET Study.

Written based on 1 research study on PubMed, searched on 15 Nov 2026.

What was studied

This study looked at eosinophilic esophagitis, or EoE, in adults and teens. It used data from the phase 3 trial LIBERTY EoE TREET. People with active EoE got dupilumab 300 mg each week, or a dummy drug. Chance decided who got which, for 24 weeks. Then people took dupilumab up to week 52. Doctors scored the food pipe on a scope test, using its worst area. This was an extra look at the data, done after the trial.

What they found

At 24 weeks, scope scores improved more with dupilumab than with the dummy drug. This was true for signs of inflammation. It was also true for signs of scarring and narrowing. Each part of the score also improved more with dupilumab. More people on dupilumab reached a score of 2 or less. More also reached a score of 0, meaning a normal look. These gains lasted up to week 52. Gains over the dummy drug were seen in people with an inflammation pattern. They were also seen in people with a mixed inflammation and scarring pattern.

What it means for patients

The authors say dupilumab improved how the food pipe looked on scope tests. It eased both inflammation and scarring signs. At 24 weeks, more people had a normal-looking food pipe than with the dummy drug. The authors say these gains held up to week 52.

Why it is not certain yet

This analysis was done after the trial, not planned at the start. After week 24, everyone took dupilumab. So there was no dummy drug group to compare with after that. The abstract gives scope scores, not how people felt. It also does not say how many people took part. It does not report side effects.

Source

Dupilumab Improves Endoscopic Features in Adult and Adolescent Patients with Eosinophilic Esophagitis: Post Hoc Analysis of LIBERTY EoE TREET Study.

PubMed · PMID 42658181

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Eosinophilic oesophagitis publications